Navigation Links
AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents
Date:3/28/2009

ROCKVILLE, Md., March 28 /PRNewswire-USNewswire/ -- Heart disease patients 65 and older who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart attack than people fitted with stents not coated with medication, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the American College of Cardiology's National Cardiovascular Data Registry.

The comparative effectiveness study of 262,700 Medicare patients who received stents - spring-like tubes to keep heart vessels open - is the largest ever to compare drug-coated stents with bare metal ones. It is being presented March 28 at the American College of Cardiology's 58th Annual Scientific Session in Orlando, Florida.

A team of researchers from Duke University, AHRQ and Kaiser Permanente found that, compared with patients who received bare metal stents, those fitted with stents coated with medication, called drug-eluting stents, had an 18 percent better survival rate over the 30-month study period and were 16 percent less likely to suffer a heart attack.

"The findings provide important new evidence for decision making by heart disease patients and their physicians," said AHRQ Director Carolyn M. Clancy, M.D. "These results should help resolve many lingering questions regarding the safety of drug-eluting stents in recent years."

HHS' Food and Drug Administration approved two stents coated with drugs in 2003 and 2004, but then issued precautionary advisories in 2006 after receiving scattered reports of blood clot formation, or thrombosis, and deaths. Subsequent clinical trials and other studies produced conflicting results.

The researchers in the AHRQ-funded study found that 16.5 percent of the patients implanted with bare metal stents died within 30 months of implantation, compared with 13.5 percent of those with
'/>"/>

SOURCE Agency for Healthcare Research & Quality
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...ca, Nov. 26 The 2009 Frost & S...the Generic Pharmaceutical Market is presented to ...ttp://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO...llowing criteria were used to benchmark Cipla Medp...trategy and implementation, degree of innovation i...
(Date:11/25/2009)... American Scientific Reso...pleased to announce that they have opened a region...hanghai, China. ,, ASR has been able to secure ...for the development and production of current and ... adults to be distributed and sold globally. Curr...
(Date:11/25/2009)...PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or...r, manufacturer and supplier of premium diagnostic...edicated to serving the healthcare needs of women,...ociety of North America (RSNA) at McCormick Place ...o highlight our new SecurView(®) DX multimoda...
Breaking Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4American Scientific Resources Inc. Opens Shanghai Location 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4U M Doctor Working to Get Neurologists in the Game When it Comes to Sports Injuries 59318 1U M Doctor Working to Get Neurologists in the Game When it Comes to Sports Injuries 59318 2U M Doctor Working to Get Neurologists in the Game When it Comes to Sports Injuries 59318 3Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 14438 1Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 14438 2Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 14438 3Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov 11 5404 1
...ith 48-week boceprevir-based ...o reported for 28-week boceprevir arm, KENILWORTH... SGP ) today reported top-line results from a pla...revir, its investigational,oral hepatitis C protea...ustained virologic response (SVR) in patients rece...
... Sanofi,Pasteur, the vaccines division of sanofi-...luzone(R), Influenza Virus Vaccine) in the United,...lion doses of influenza,vaccine began shipping thi...009 formulation by the U.S. Food and Drug Administ... to health-care providers and to the Centers for,D...
Other Medicine Technology:Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 2Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 3Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 4Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 5Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 6Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 7Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 8Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 9Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 2Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 3Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 4Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 5
(Date:11/27/2009)...ist manufacturers who use medical load cells at th...ollars by bringing in technology partner Flintec e...pro-active medical manufacturers are calling in Fl...eir projects, ensuring that progress will not be c...ally outdated technology. , ...
(Date:11/26/2009)...r of Americans living with diabetes will nearly do... million in 2034. Over the same period, spending o...llion to $336 billion, even with no increase in th...University of Chicago report in the December issue...diabetes covered by Medicare will rise from 8.2 mi...
(Date:11/26/2009)... letters from the North Pole, Textsanta.net lets p... Santa , North Pole, AK (...iciencies at the North Pole Santa Claus has added ...the globe informed of his Christmas progress at th...department have identified a large and growing per...
(Date:11/26/2009)...amp; Ennis, P.A. is offering free nationwide confi...birth control pills who have suffered a Deep Vein ...t Attack or other related cardiac issues or had th...at 1-800-856-6405 or go to the firm’s websit...ine case evaluation form. , ...
(Date:11/25/2009)... Nov. 25 /PRNewswire/ - Sentinelle Medical Inc., a...g (MRI) coils and software and Calgary Scientific ...nologies, have introduced a web version of Aegis(T..., This innovative interface is the first truly zer...ing in the market. Calgary Scientific,s PureWeb(TM...
Breaking Medicine News(10 mins):Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3
...RNewswire-FirstCall/ -- InfoLogix, Inc. (Nas...terprise mobility solutions for the healthcare and...y has entered into an agreement with Gwinnett Med...stem in the emergency department. , , (Logo: ht...
...l 23 Valeant Pharmaceuticals International (NYSE:...rence call and a live Internet webcast along with ...:00 a.m. EDT (7:00 a.m. PDT) to discuss results fo...should dial (973) 200-3961, confirmation code 9423...
... 23 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmac...PH) (the "Company"),a U.S. pharmaceutical company ...blic of China, today announced that it has changed... that the Certificate of Amendment to the Company,...
...wswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASD...f its first quarter fiscal 2009 results conference...st Quarter Results Conference Call , , On Thursda...quarter 2009 financial results via news release at...
...ine With or Exceed Expectations , , DENVER, April...e largest air medical transportation company in th...009 earnings exceed expectations. Expected earnin...maintenance and fuel expense. , , Total community...
...al in establishing day to honor mom , , GROVE CIT...iversary for the Fraternal Order of Eagles ( htt...Durham. The step-mother and grandmother understand...day in May was designated Mother,s Day by Presiden...
Other Medicine News:Health News:InfoLogix Selected by Gwinnett Medical Center to Transform Clinical Care Through Next-Generation Mobile Communications Solution 2Health News:InfoLogix Selected by Gwinnett Medical Center to Transform Clinical Care Through Next-Generation Mobile Communications Solution 3Health News:Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009 2Health News:Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name 2Health News:Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name 3Health News:Labopharm announces details for first quarter results conference call and annual meeting 2Health News:Air Methods' Preliminary 1st Qtr. Results Exceed Expectations 2Health News:Air Methods' Preliminary 1st Qtr. Results Exceed Expectations 3Health News:Fraternal Order of Eagles Grand Madam President Celebrates Mother's Day 2
...s two system in one. Uncomplicated design and ease...es. Quick-connect angled blades of anodized alumin... visualization. Aluminium blades allow for intra-o...tractor bodies, both longitudinal and transverse, ...
Scoville Cervical Disc Retractor
...uperior retractor blade stability and image friend...ne retraction objectives. The Image-line's color-c...lade size determination. The wide range of blade o...edures. Patents pending blade hub and frame graspe...
Cervical Retractor Handle - Small
Medicine Products: